Overview of a Phase II clinical trial of isatuximab
The use of CAR T-cells in multiple myeloma
Adam Cohen et al.
Which is the best combination therapy in relapsed and refractory multiple myeloma?
How immunomodulatory drugs have reinforced the value of the immune system in multiple myeloma
Jesús San Miguel
Immunotherapy highlights from ICML 2017